Disposition and biotransformation of the antiretroviral drug nevirapine in humans.
about
Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit allNon-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerabilityA sensitive and specific liquid chromatography/tandem mass spectrometry method for quantification of nevirapine and its five metabolites and their pharmacokinetics in baboonsQuantifying the metabolic activation of nevirapine in patients by integrated applications of NMR and mass spectrometriesGenome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population.Protein adducts as prospective biomarkers of nevirapine toxicity.Measuring the overall genetic component of nevirapine pharmacokinetics and the role of selected polymorphisms: towards addressing the missing heritability in pharmacogenetic phenotypes?Comparative study of the effects of antituberculosis drugs and antiretroviral drugs on cytochrome P450 3A4 and P-glycoprotein.Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics.HIV associated nephropathy: a treatable condition.Effect of Host Genetic Variation on the Pharmacokinetics and Clinical Response of Non-nucleoside Reverse Transcriptase Inhibitors.Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates.CYP2B6 c.983T>C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations.Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance)Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship.Pharmacogenomics of antimicrobial agents.Sensitive enzyme immunoassay for measuring plasma and intracellular nevirapine levels in human immunodeficiency virus-infected patientsOral lesions associated with nevirapine-related Stevens Johnson syndrome: A report of four casesThe Expanding Class of Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of HIV-1 InfectionThe effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, UgandaCytochrome P450 2B6 genetic variants are associated with plasma nevirapine levels and clinical response in HIV-1 infected Kenyan women: a prospective cohort study.Nevirapine-Based Antiretroviral Therapy Impacts Artesunate and Dihydroartemisinin Disposition in HIV-Infected Nigerian Adults.Use of antineoplastic agents in patients with cancer who have HIV/AIDS.Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descentEffects of CYP2B6 and CYP1A2 Genetic Variation on Nevirapine Plasma Concentration and Pharmacodynamics as Measured by CD4 Cell Count in Zimbabwean HIV-Infected Patients.Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adultsPharmacological and clinical evidence of nevirapine immediate- and extended-release formulationsMultiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians.Pharmacokinetics of phase I nevirapine metabolites following a single dose and at steady state.Prevalence of UGT1A9 and UGT2B7 nonsynonymous single nucleotide polymorphisms in West African, Papua New Guinean, and North American populations.Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmissionLack of clinically significant drug interactions between nevirapine and buprenorphine.Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children.Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection.Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics.Pharmacokinetic assessment of nevirapine and metabolites in human immunodeficiency virus type 1-infected patients with hepatic fibrosisInfluence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal modelsAssociations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans.Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi.Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients.
P2860
Q24609011-0171F1D9-6494-423F-AC9C-B7094A93F044Q24628212-9BD2560C-7FB5-4FB2-8DC9-54BEB096B54DQ33514519-C0B68C2E-9FBA-40CB-BE89-EDE435663660Q33574656-3E56697D-CBDD-4CC9-9435-BE59686DE301Q33589777-82956BDF-F36C-4251-B983-71E0BE26671AQ33681307-EA73F4D6-45CC-40C6-8F05-48D8FF93D40BQ33720712-824609AA-401C-4F4E-9BA9-87A177F2F889Q33797986-29AD224E-C8F5-46A3-B5C5-FDC6F29579EFQ34149022-FB0D27FC-ADFC-410C-A9C2-9B958A1A79A1Q34208327-E36B9621-E3F9-4D48-A165-A1F0C1D45346Q34443184-CA55C96F-FAE7-44DC-91B0-8FA5C602A910Q34483505-555DADB0-62E8-455D-BC8D-2A43801559EFQ34495636-E2D7D050-8098-4AD4-926C-DE9C3D12FB5FQ34570873-91DD52BF-E370-4FD7-90E6-9A6FEB1B4C86Q34710641-6A615717-0544-42AA-ABFA-F0BD95F1F2ADQ34977413-541B245C-CDC0-429B-AFD1-1FAFF5E4DA0AQ35006387-0EA644F8-6C24-40A6-BAA2-2C391DFB9DD2Q35075291-862F6D39-EB41-409D-9FF4-271A5D2A8F97Q35111300-AF9AEE18-800D-4371-BE46-6B6383A6E914Q35154032-9A68EE0B-D0F9-4F3E-9D7A-A6AE3516878FQ35426496-5012CC0E-6D8E-4AC8-8265-C60F8109C4CBQ35829744-15ABF5D6-AE87-4A77-A911-773850483905Q35932561-A0E7FF83-E25D-4C69-BF89-1152CDB337C0Q36070182-D28038ED-AB86-4F9E-AB15-D469D473A3F0Q36074119-73FB4E5E-1188-4732-8C31-2C0988C6FCE5Q36300127-1A3AC58C-F7D4-4FE0-86BC-DD152FCCED80Q36410952-5F732562-A04A-403A-8C19-7656E28297F1Q36650954-03A4BD6E-996B-4546-BC56-18915CC18B01Q36785839-79B65EFF-23D0-4AA8-90BD-B1B11DE652BFQ36959519-89A8E6DE-2A1F-407B-98C0-E6F0E3A99C0EQ37037070-1C0B1DB9-0C89-4180-93F3-C181C082B047Q37045349-DA922A9F-F514-4143-8DA1-0D66887DF7B3Q37096787-39C0C8EA-2F2B-4D95-B65A-27B5B484F416Q37361492-2252B326-DEAE-4A30-B8DD-FCA72C3E64FCQ37371310-AF943E1F-4A5B-4495-8097-833713079804Q37392929-088B1963-6BD5-4342-8D95-10744420CA48Q37395532-60200B00-5F54-4C9F-95D8-408D91E2BA67Q37444323-A0D2EF84-1129-48DD-979B-14638E3778E1Q37544678-5EFA93AE-25C0-4315-B338-C8A830EF2B73Q37598731-B5E42F0D-FD7C-4BEC-90DC-E6A0F8192E18
P2860
Disposition and biotransformation of the antiretroviral drug nevirapine in humans.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Disposition and biotransformation of the antiretroviral drug nevirapine in humans.
@en
Disposition and biotransformation of the antiretroviral drug nevirapine in humans.
@nl
type
label
Disposition and biotransformation of the antiretroviral drug nevirapine in humans.
@en
Disposition and biotransformation of the antiretroviral drug nevirapine in humans.
@nl
prefLabel
Disposition and biotransformation of the antiretroviral drug nevirapine in humans.
@en
Disposition and biotransformation of the antiretroviral drug nevirapine in humans.
@nl
P2093
P1476
Disposition and biotransformation of the antiretroviral drug nevirapine in humans
@en
P2093
MacGregor T
P304
P577
1999-08-01T00:00:00Z